KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Classic Hodgkin Lymphoma in the Older Adult: What's New?

Carrie Sha, Sarah C Rutherford

Hematol Oncol Clin North Am 40(2) 213-229

PMID41708412
PMCID-
DOI10.1016/j.hoc.2025.12.009
发表日期2026-02-18
摘要

摘要

Outcomes for older patients with classic Hodgkin lymphoma (cHL) are improving with the inclusion of novel agents into frontline therapy. The sequential brentuximab vedotin (BV) and doxorubicin, vinblastine, dacarbazine (AVD) regimen was standard of care for many older adults with cHL until the checkpoint inhibitor nivolumab (N) and AVD showed marked tolerability and efficacy compared with BV-AVD in the SWOG S1826 randomized, phase 3 clinical trial. Palliative regimens including BV-N are options for patients who are anthracycline-ineligible, and a forthcoming clinical trial will investigate the combination of gemcitabine and pembrolizumab in this population.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。